Gainers & Losers Of The Day: PULM, ETRM, SMMT, BVX, ARQL...

Catabasis Pharmaceuticals Inc. lost over 70% on Wednesday as Part B of its phase II trial of Edasalonexent in Duchenne Muscular Dystrophy did not meet primary efficacy endpoint.

from RTT - Biotech http://ift.tt/2jXLJm8
via IFTTT